Penn Medicine
Help | Search | Site Map | Contact   
faculty photo

Selina M. Luger, M.D.

Professor of Medicine at the Hospital of the University of Pennsylvania
Attending Physician , Hospital of the University of Pennsylvania
Member , Abramson Cancer Center, University of Pennsylvania
Director, Outpatient Practice, Stem Cell Transplant & Hematological Malignancies, Hospital of the University of Pennsylvania
Director, Leukemia Program, Abramson Cancer Center, Perelman School of Medicine
Member, Electronic Medical Record Oversight Committee
Member, Sunrise Physician Advisory Board
Chair, Hematology-Oncology Epic Governance, Perelman School of Medicine, University of Pennsylvania
Member, Clinical Leadership Committee, Department of Medicine
Member, Epic Operations Committee, Hospital of the University of Pennsylvania
Medical Board, Member, Executive Committee, Hospital of the University of Pennsylvania
Member, Penn Chart Development Committee, Hospital of the University of Pennsylvania
Department: Medicine

Contact information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
12th Floor, South Pavilion
Office #12-101
34th and Civic Center Blvd
Philadelphia, PA 19104
Office: 215-614-1847
Fax: 215-662-4064
Education:
A.B. (Biochemistry)
Harvard University, 1982.
M.D.CM (Medicine)
McGill University, 1987.
Post-Graduate Training
Intern, Internal Medicine , Presbyterian University Hospital, Pittsburgh, 1987-1988.
Resident, Internal Medicine , Presbyterian University Hospital, Pittsburgh, 1988-1990.
Fellowship, Hematology-Oncology , University of Pennsylvania, Philadelphia, 1990-1993.
Certifications
Royal College of Physicians & Surgeons of Canada, 1990.
ABIM/Internal Medicine, 1990.
ABIM/Medical Oncology, 1993.
ABIM/Hematology, 2006.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

Leukemia, myelodysplastic syndrome, myeloproliferative disorders
MDS, AML, CML, ALL

Description of Clinical Expertise

hematologic malignancies, leukemia, AML, ALL, CML, myelodysplastic syndrome, MDS, myeloproliferative disorders, stem cell transplantation, bone marrow transplant

Selected Publications

Pasquini MC, Zhang MJ, Medeiros BC, Armand P, Hu ZH, Nishihori T, Aljurf MD, Akpek G, Cahn JY, Cairo MS, Cerny J, Copelan EA, Deol A, Freytes CO, Gale RP, Ganguly S, George B, Gupta V, Hale GA, Kamble RT, Klumpp TR, Lazarus HM, Luger SM, Liesveld JL, Litzow MR, Marks DI, Martino R, Norkin M, Olsson RF, Oran B, Pawarode A, Pulsipher MA, Ramanathan M, Reshef R, Saad AA, Saber W, Savani BN, Schouten HC, Ringdén O, Tallman MS, Uy GL, Wood WA Jr, Wirk B, Pérez WS, Batiwalla M, Weisdorf DJ: Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies. Biol Blood Marrow Transplant. 22(2): 248-57, Feb 2016

Kumar AJ, Gimotty PA, Gelfand J, Buck G, Rowe JM, Goldstone AH, Fielding A, Marks DI, Litzow M, Paietta E, Lazarus HM, Tallman MS, Luger SM, Loren AW.: Delays in Post-Remission Chemotherapy for Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia are Associated with Inferior Outcomes in Patients who Undergo Allogeneic Transplant: An Analysis from ECOG 2993/MRC UK ALLXII. Am J Hematol. Jul 2016.

Luskin MR, Ganetsky A, Landsburg DJ, Loren AW, Porter DL, Nasta SD, Svoboda J, Luger SM, Frey NV.: Nelarabine, cyclosphosphamide and etoposide for adults with relapsed T-cell acute lymphoblastic leukaemia and lymphoma. Br J Haematol 174(2): 332-4, Jul 2016.

Luskin MR, Carroll M, Lieberman D, Morrissette JJ, Zhao J, Crisalli L, Roth DB, Luger SM, Porter DL, Reshef R.: Clinical Utility of Next Generation Sequencing for Oncogenic Mutations in AML Patients Undergoing Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant. Jul 2016.

Luskin MR, Gimotty PA, Smith C, Loren AW, Figueroa ME, Harrison J, Sun Z, Tallman MS, Paietta EM, Litzow MR, Melnick AM, Levine RL, Fernandez HF, Luger SM, Carroll M, Master SR, Wertheim GB.: A clinical measure of DNA methylation predicts outcome in de novo acute myeloid leukemia. JCI Insight. 1(9), Jun 2016.

Kumar AJ, Vassilev P, Loren AW, Luger SM, Reshef R, Gill S, Smith J, Goldstein SC, Hexner E, Stadtmauer EA, Porter D, Frey NV.: Time to Unrelated Donor Leukocyte Infusion is Longer, but Incidence of GVHD and Overall Survival are Similar for Recipients of Unrelated DLI Compared to Matched Sibling DLI. Am J Hematol 91(4): 426-9, Jun 2016.

Hexner EO, Luger SM, Reshef R, Jeschke GR, Mangan JK, Frey NV, Frank DM, Richman LP, Vonderheide RH, Aqui NA, Rosenbach M, Zhang Y, Chew A, Loren AW, Stadtmauer EA, Levine BL, June CH, Emerson SG, Porter DL.: Infusion of CD3/CD28 costimulated umbilical cord blood T cells at the time of single umbilical cord blood transplantation may enhance engraftment. Am J Hematol. 91(5): 453-60, May 2016.

Yam C, Crisalli L, Luger SM, Loren AW, Hexner EO, Frey NV, Mangan JK, Gao A, Stadtmauer EA, Porter DL, Reshef R.: Unrelated donors are associated with improved relapse-free survival compared to related donors in patients with myelodysplastic syndrome undergoing reduced intensity allogeneic stem cell transplantation. Am J Hematol. May 2016.

Sloan CE, Luskin MR, Boccuti AM, Sehgal AR, Zhao J, Daber RD, Morrissette JJ, Luger SM, Bagg A, Gimotty PA, Carroll M.: A Modified Integrated Genetic Model for Risk Prediction in Younger Patients with Acute Myeloid Leukemia. PLoS One. 11(4), Apr 2016.

Luskin MR, Lee JW, Fernandez HF, Abdel-Wahab O, Bennett JM, Ketterling RP, Lazarus HM, Levine RL, Litzow MR, Paietta EM, Patel JP, Racevskis J, Rowe JM, Tallman MS, Sun Z, Luger SM.: Benefit of high dose daunorubicin in AML induction extends across cytogenetic and molecular groups: updated analysis of E1900. Blood 127(12): 1551-8, Mar 2016.

back to top
Last updated: 08/05/2016
The Trustees of the University of Pennsylvania
 
© The Trustees of the University of Pennsylvania. Site best viewed with Mozilla, NN, IE, or Safari.
SOM Home International Programs Penn Alumni Clinical Trials Centers and Institutes Departments Faculty Research Education Administration